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Abstract
Background: The purpose of this retrospective study was to determine whether RFA could provide an alternative
treatment modality for selected patients who are not candidates for hepatic resection.
Methods: A total of 18 consecutive patients with liver metastases alone from gastric cancer treated with radiofrequency
ablation (RFA, n = 11) or hepatic resection (HR, n= 7) at Seoul St. Mary’s Hospital, Korea, between January 2000 and
September 2014, were enrolled.
Results: The median OS and DFS in the RFA group were 40.5 ± 22.3 and 10.3 ± 1.07 months, respectively. There was no
significant difference between the RFA and HR groups in terms of baseline characteristics except for performance status.
Mean survival and DFS times of all patients were 60.1 ± 9.4 and 40.9 ± 10.2 months, respectively. Mean OS times in the HR
and RFA groups were 67.5 ± 15.4 and 51.1 ± 9.8 months (P = 0.671), respectively, and the mean DFS time in the HR group
(74.1 ± 14.2 months) was longer than that in the RFA group (26.9 ± 9.2 months), but the difference was not significant
(P = 0.076).
Conclusions: In patients who are not candidates for surgical treatment, RFA may be an alternative to HR.
Keywords: Gastric cancer, Liver metastases, Radiofrequency ablation
Background
Gastric cancer (GC) is the second leading cause of
cancer-related deaths worldwide [1]. Survival from GC is
inversely related to its staging at diagnosis. The liver is
the most common site of hematogenous metastases
from gastric cancer. Approximately 4–14% of patients
with GC develop synchronous or metachronous liver me-
tastases during the course of the disease, and the prognosis
for these patients is poor [2–4]. Among them, half of the
patients are diagnosed with exclusively hepatic metastases
but the others have concurrent extrahepatic disease, such
as peritoneal dissemination, extensive lymph node
metastases, or direct neoplastic infiltration of adjacent
organs [2–6]. Thus, therapeutic decisions in these patients
are a challenge for surgeons and oncologists.
Surgical resection, non-surgical ablation techniques,
and systemic chemotherapy are options for therapy.
Hepatic resection (HR) has been considered to be the
most effective treatment for patients with colorectal liver
metastases, with a 5-year survival rate of 40–50% [7, 8].
It provides local control of disease, improved disease-
free survival (DFS), and better 5-year overall survival
(OS) than chemotherapy alone [4]. However, because of
aggressive oncological features, limited surgical indications,
post-hepatectomy liver failure, and frequent peritoneal dis-
semination, not all patients with gastric liver metastases are
candidates for HR. For example, many patients with gastric
liver metastases have accompanying peritoneal dissemin-
ation, extensive lymph node metastases, direct invasion of
adjacent organs, and metastatic tumors involving multiple
segments, which preclude HR at the time of presentation.
Thus, various treatments such as systemic chemotherapy,
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hepatic arterial infusion (HAI) chemotherapy, radiotherapy,
and radiofrequency ablation (RFA) have been proposed to
improve outcomes [9–11].
RFA has been considered a less invasive therapeutic
choice for hepatocellular carcinoma, especially with
small tumors (≤3 cm), and has been used increasingly in
the treatment of colorectal or gastric liver metastases
because of its safety and wide applicability. There have
been remarkable developments in RFA techniques for
oncological applications [12]. Different retrospective
studies have demonstrated that RFA combined with
systemic chemotherapy is effective in the treatment of
hepatic metastases from GC. However, because of the
low number of patients with gastric liver metastases,
prospective clinical trials evaluating the long-term out-
comes of RFA for liver metastases of GC are still lacking
and predicting which patients will benefit from RFA or
HR is still unclear.
The purpose of this retrospective study was to deter-
mine whether RFA can provide an alternative treatment
for selected patients. We compared the long-term results
for GC patients with synchronous or metachronous liver
metastases, who were treated with RFA or HR. We report
our experiences with 18 patients with liver metastases




The institutional review board of Seoul St. Mary’s Hospital
approved the retrospective analysis of anonymous data.
The requirement for written informed consent was
waived, because the patient records were anonymized and
deidentified prior to analysis.
In total, 18 patients with solitary liver metastases from
GC, treated with RFA or surgical resection at Seoul St.
Mary’s Hospital, Korea, between January 2000 and
September 2014, were enrolled. Clinicopathological
information was examined retrospectively.
Histological types of primary GC were categorized
as differentiated (well-differentiated, moderately differ-
entiated, or papillary) and undifferentiated (signet-ring
cell carcinoma, poorly differentiated, or mucinous).
All histopathological information was evaluated
according to the International Union Against Cancer
(UICC) TNM classification (7th edition) [13]. Patients
with synchronous hepatic metastases were diagnosed
at the time of presentation with GC, on routine
staging with computed tomography. Patients with
metachronous metastases were considered to be clear
of hepatic metastases at the initial curative-intent
surgery with R0 resection, but subsequently became
symptomatic on follow-up and were diagnosed with
hepatic metastases on radiological images.
The feasibility and safety of RFA were discussed with
gastric surgeons, medical oncologists, and interventional
radiologists. We considered hepatic resection when
complete resection (R0) could be achieved successfully
and hepatic reservoir function would be preserved after
surgery. RFA was considered for patients with unresect-
able (by any means) disease or high operative risk, such
as co-morbidities, poor performance status, and anato-
mical difficulties that precluded HR or when patients
refused surgical treatment. Furthermore, palliative
intended RFA was considered for metastatic hepatic
lesions > 3 cm in size. Another inclusion criteria was that
complete ablation of the metastatic lesion was feasible.
Patients with extrahepatic metastases were excluded.
The primary endpoints were overall survival (OS) and
disease-free survival (DFS).
Statistical analysis
Clinical outcomes and survival rates in patients treated
with RFA and HR were compared using t-tests and χ2
tests, as appropriate. Statistical analyses were performed
using SPSS software (ver. 12.0; SPSS Inc., Chicago, IL).
Continuous data were compared using two-tailed Stu-
dent’s t-tests and categorical data were compared using
χ2 tests. Survival was analyzed using the Kaplan-Meier
method and compared using the log-rank test. Overall
survival duration was calculated in months from the
date of initial RFA or HR to death or last visit to the
clinic. Disease-free survival time was calculated in
months from the date of RFA (last RFA in cases where
patients underwent repeated procedures) or HR to local
relapse of tumor, death, or last follow-up. The Cox
regression method was used to establish independent
predictors for survival and DFS. Multivariate analysis
was performed with Cox’s proportional hazard model
and factors with p values < 0.1 in univariate analyses
were included. A P value of < 0.05 was considered to
indicate statistical significance.
RFA procedure
All RFA procedures were performed after ultrasound (US)
examinations to assess the feasibility of US-guided
percutaneous RF ablation. One of two board-certificated ra-
diologists performed all RFA procedures with US guidance
using a commercially available system (Radionics, Cool-Tip
system; Burlington, MA, USA) and single-needle electrodes
with a 2- or 3-cm active tip. Moderate sedation was used
with intravenous injections of pethidine hydrochloride (Jeil
Pharm. Co., Ltd.), fentanyl citrate (Daihan Pharm. Co., Ltd,
Seoul, Korea), or midazolam (Buqwang, Seoul, Korea). Two
or more grounding pads were attached to the patient’s legs.
The electrode was inserted percutaneously into the lesion
and a route to the lesion was monitored using US. The
ablation was performed with gradually increased generator
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output power during 12 min for each lesion. An ablative
margin of at least 0.5 cm surrounding the tumor was the
therapeutic goal and the achievement of this goal was eval-
uated by immediate follow-up computed tomography (CT).
If residual viable tumor was found on CT, an additional RF
ablation was done to achieve a technically successful RFA.
Follow-up
RFA efficacy was evaluated with a contrast-enhanced CT
scan 1 month after RFA. The tumor was considered to
exhibit complete necrosis on the basis of two findings:
(1) no contrast enhancement was found within the
tumor, and (2) the margins of the ablated zone were
clear and smooth. In cases where residual tumor was
found on the CT scan 1 month after RFA, a repeated
procedure was performed until the imaging scan exhib-
ited no contrast enhancement. After confirming
complete destruction of metastatic tumors, patients were
followed with repeated CT scan every 3 months during
the first year and every 6–12 months after the first year.
Table 1 Baseline characteristics between HR and RFA groups
Characteristics HR (N = 7) n (%) RFA (N = 11) n (%) P* value
Sex
Male 5 (71.4) 10 (90.9) 0.280
Female 2 (28.6) 1 (9.1)
Age
<60 2 (28.6) 4 (36.4) 0.732
≥60 5 (71.4) 7 (63.6)
Comorbidity
No 5 (71.4) 6 (54.5) 0.474
Yes 2 (28.6) 5 (45.5)
ECOG PS
0 7 (100) 4 (36.4) 0.026
1 0 (0) 5 (45.5)
2 0 (0) 2 (18.2)
Tumor location
Upper 1/3 0 (0) 1 (9.1) 0.434
Middle 1/3 2 (28.6) 1 (9.1)
Lower 1/3 5 (71.4) 9 (81.8)
Differentation
Differentiated 4 (51.7) 7 (63.6) 0.783
Undifferentiated 3 (42.9) 4 (36.4)
Leuren
Intestinal 3 (42.9) 6 (54.5) 0.629
Diffuse&Mixed 4 (51.7) 5 (45.5)
Primary Tumor size
<3 cm 1 (14.3) 1 (9.1) 0.829
≥3 cm 6 (85.7) 10 (90.9)
Lymphatic invasion
LI (−) 3 (42.9) 1 (9.1) 0.093
LI (+) 4 (57.1) 10 (90.9)
Vascular invasion
VI (−) 4 (57.1) 8 (72.7) 0.494
VI (+) 3 (42.9) 3 (27.3)
Perineural invasion
NI (−) 4 (57.1) 8 (72.7) 0.494
NI (+) 3 (42.9) 3 (27.3)
T stage
T1-2 1 (14.3) 5 (45.5) 0.171
T3-4 6 (85.7) 6 (54.5)
N stage
N0 2 (28.6) 1 (9.1) 0.280
N1-3 5 (71.4) 10 (90.9)
AJCC 7th stage
Stage 1–2 3 (42.9) 5 (45.5) 0.914
Table 1 Baseline characteristics between HR and RFA groups
(Continued)
Stage 3-4 4 (57.1) 6 (54.5)
Chemotherapy
CTx (−) 1 (14.3) 1 (9.1) 0.732
CTx (+) 6 (85.7) 10 (90.1)
Number of metastatic Tumor
Single 5 (71.4) 8 (72.7) 0.952
Multiple 2 (28.6) 3 (27.3)
Size of metastatic Tumor
<3cm 4 (42.9) 6 (54.5) 0.914
≥3cm 3 (57.1) 5 (45.5)
Lobar distribution
Unilobar 6 (85.7) 10 (90.9) 0.732
Bilobar 1 (14.3) 1 (9.1)
Pre-treatment
Chemotherapy
CTx (−) 7 (100) 7 (63.6) 0.070
CTx (+) 0 (0) 4 (36.4)
Post-treatment Chemotherapy
CTx (−) 1 (14.3) 7 (63.6) 0.040
CTx (+) 6 (85.7) 4 (36.4)
Complication
No 5 (71.4) 11 (100) 0.060
Yes 2 (28.6) 0 (0)
HR hepatic resection, RFA radiofrequency ablation, ECOG Eastern Cooperative
Oncology Group; PS Performance Status, LI lymphatic invasion, VI venous
invasion, NI perineural invasion, CTx chemotherapy
*log-rank test
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Results
Between January 2000 and December 2014, 11 patients
underwent RFA and 7 underwent HR for synchronous
or metachronous liver metastases of GC at our institu-
tion. Table 1 summarizes the baseline characteristics of
the two groups. All patients received curative resections
with D2 lymph node dissection for primary GC. Of the
patients, 15 (83.3%) were males and 3 (16.7%) were fe-
males. Their median age was 66 years (range, 44–85).
There were 6 patients with comorbidities in the RFA
group and 2 in the HR group; however, no significant
difference was observed between the groups. Regard-
ing performance status, all patients in the HR group
had an ECOG score of 0, whereas 5 and 2 patients in
the RFA group had ECOG scores of 1 and 2, respec-
tively (P = 0.026). The mean survival and DFS times
of all patients were 60.15 ± 9.44 and 40.9 ±
10.26 months, respectively. There was no significant
difference between the groups in terms of baseline
characteristics or tumor-related factors except for sys-
temic chemotherapy after HR or RFA. Systemic
chemotherapy after procedures was administered in
87.5% of patients who underwent HR and 36.4% of
patients who underwent RFA. The chemotherapeutic
regimens included FOLFOX (5-FU, leucovorin, oxali-
platin) and oral agents (tegafur/uracil). Mean overall
survival times in the HR and RFA groups were 67.52
± 15.45 and 51.11 ± 9.87 months, respectively: there
was no significant difference in terms of OS between
the groups (Fig. 1; P = 0.671). The mean DFS times in
the HR group (74.16 ± 14.25 months) was longer than
that in the RFA group (26.90 ± 9.24 months), but the
difference was not significant (Fig. 2; P = 0.073).
There were 2 patients with postoperative complica-
tions (intra-abdominal abscesses) in the HR group,
meeting the Clavien-Dindo classification grade IIIa.
However, there was no case of complications in the RFA
group.
Gender and histological differentiation were indepen-
dent risk factors for OS in univariate analyses, but neither
was associated with overall survival in a multivariate ana-
lysis (Table 2). Regarding DFS, univariate log-rank test
analysis revealed that vascular invasion of the primary GC
and type of treatment were significant prognostic factors
(P = 0.049), but neither showed a statistically significant
difference in a multivariate analysis (Table 3).
RFA treatment
Table 4 summarizes clinical characteristics and prognostic
results. One female patient and 10 of the 11 patients had
lymph node metastases. Only Patient 4 was diagnosed
with synchronous liver metastases at the time of evalu-
ation for primary GC. He was administered 6 cycles of
neoadjuvant chemotherapy (Taxol, Cisplatin) before main
treatment and RFA was performed at the time of surgery.
Patients 2 and 5 had alcoholic hepatitis and history of
cerebrovascular disease, respectively, and their ECOG
scores were 1. Patient 8 was diagnosed with toxic hepatitis
because of prior chemotherapy. Patient 9 had interstitial
lung disease and his ECOG score was 2. Finally, Patient 7
refused surgical treatment for liver metastases because of
poor general condition (ECOG score 1) and low tolerance
to prior chemotherapy.
Complete ablation was achieved in 9 patients; 2
patients whose 1 month follow-up CT scans revealed
remaining viable tumor underwent repeat ablations and
Fig. 1 Overall survival of all patients treated with HR and RFA (P = 0.671)
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all residual tumor was ablated successfully by the second
RFA. Only 4 patients received systemic chemotherapy
after RFA, indicating that most patients in the RFA
group had poor performance status. Hepatic metastases
recurred in 5 patients, lung metastases in 1 patient, and
Virchow’s node in 1 patient. Of these, 2 patients under-
went RFA again and 2 received second-line systemic
chemotherapy. Systemic chemotherapy was administered
until disease progression or intolerance of the treatment.
Two of the 11 patients survived more than 5 years after
initial RFA (Patients 1, 4). Of these, Patient 4 developed
a suspicious metastatic pulmonary nodule 41 months
after the initial RFA, which was confirmed as an inflam-
matory nodule by positron emission tomography; it
regressed spontaneously. The median OS and DFS were
40.5 ± 22.37 and 10.30 ± 1.07, respectively.
Discussion
Liver metastasis from GC is generally staged according to
the system of the Japanese Gastric Cancer Association
(H0, no liver metastasis; H1, liver metastases limited to
one lobe of the liver; H2, isolated diverse metastases in
both lobes of the liver; H3, multiple distributed metastases
in both lobes of the liver) [14]. The prognosis of GC liver
metastases is known to be poor with survival of 3–5
months without an effective treatment [15]. For these pa-
tients, systemic chemotherapy can be a standard approach
and surgical resection has recently been reported to
prolong survival in selected patients [16–18].
HR for metastatic tumors has been most recognized
treatment option in patients with colorectal cancer, with
5-year survival rates of 37–58% [7]. However, these
excellent results with colorectal cancer have not been
achieved in gastric cancer, seemingly due to the
biological aggressiveness of the disease. Furthermore,
not all patients with liver metastases from GC are candi-
dates for surgical resection because of tumor location,
functional hepatic reserve after surgery, comorbidities,
and synchronous peritoneal dissemination. These pa-
tients with unresectable liver metastases have received
systemic chemotherapy; however, the results have been
disappointing.
Recently, given the disappointing prognosis of ‘conven-
tional’ systemic chemotherapy for GC with liver metasta-
ses, RFA has been regarded as an alternative to HR for
treating primary or metastatic tumors in selected patients
[19, 20]. Several groups have reported the benefit of RFA
in treating hepatic metastases from GC [6, 9, 11, 21]. Kim
et al. [10] addressed the rationale for RFA, suggesting that
cytoreductive procedures enable chemotherapy to be
more effective and that removal of an isolated metastatic
deposit can prevent further dissemination of the disease
to other sites. Dittmar et al. [6] concluded that RFA may
be a useful alternative in patients where surgery is not
feasible in a retrospective study with 15 patients who
underwent liver resection or RFA for hepatic metastases
from GC. Furthermore, Chen et al. [9] argued that
patients with solitary liver metastases benefit from RFA,
which is minimally invasive and considered a safe moda-
lity. However, few studies have compared prognosis after
treatment of GC liver metastases with RFA or HR, and
the available results have been conflicting. Hwang et al.
[22] considered 72 patients with metachronous metastases
subjected to different treatments, but not to hepatectomy.
Of their cohort, the 15 patients without extrahepatic
disease treated by RFA combined with systemic
Fig. 2 Disease-free survival of all patients treated with HR and RFA (P = 0.073)
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Table 2 Univariate and multivariate analysis of gastric cancer
patients’ clinicopathological features for survival
















































Type of treatment 0.671
Hepatic resection 68.6
RFA 47.6
5-YSR 5-year survival rate, HR hazard ratio, LI lymphatic invasion, VI venous
invasion, NI perineural invasion, RFA radiofrequency ablation
*log-rank test
Table 3 Univariate and multivariate analysis of gastric cancer
patients’ clinicopathological features for DFS



















Vascular invasion 0.049 0.061



























Type of treatment 0.073 0.072
Hepatic resecction 80.0 Ref
7.171
RFA 30.3
DFS disease-free survival, HR hazard ratio, LI lymphatic invasion, VI venous
invasion, NI perineural invasion, RFA radiofrequency ablation
*log-rank test
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chemotherapy had a median survival of 22 months, with
3- and 5-year survival rates of 50 and 40%, respectively,
similar to those reported in the best surgical series. Given
this background, we performed RFA in patients with liver
metastases from GC and compared the results with those
of HR.
RFA is a less invasive procedure than surgical resection
and can be performed repeatedly in case of incomplete ab-
lation or recurrent tumors safely. In our study, 2 patients
underwent repeated RFA for remnant viable tumors.
However, several studies have noted that RFA was asso-
ciated with a higher recurrence rate. Those studies
reported that tumors > 3 cm in diameter were associated
with local recurrence after RFA [23–25].
In our cohort, we found that the mean DFS in the HR
group was longer than that in the RFA group (74.16 ± 14.25
vs. 26.90 ± 9.24; P = 0.073; Fig. 2). The mean survival times
were 64.52 ± 15.45 and 51.11 ± 9.87 months for those
patients who underwent HR or RFA for liver metastases,
respectively; there was no significant difference in OS. From
this perspective, although HR was superior to RFA in terms
of DFS, RFA could be an alternative to HR, especially in pa-
tients who have comorbidities or borderline resectability
because of the less invasive nature and repeatability of the
procedure. In our cases, 2 patients lived more than 5 years
after procedures, and one of them (Patient 1 in Table 3)
underwent repeated RFA for incomplete ablation.
Recently, several factors, such as the number of meta-
static tumors, maximal size, status of lobar distribution,
chronicity, and combination with systemic chemotherapy,
were identified to be independent prognostic factors after
treatment of liver metastases from GC [26, 27]. However,
in our multivariate analysis, none of these factors was as-
sociated with OS or DFS. Therefore, we believe that this
procedure can be applied to carefully selected patients,
even from a point of oncological view.
This study has several limitations including its retro-
spective nature and small sample size. Moreover, 3
patients in the HR group were lost to follow-up during
the study period, so we were unable to collect information
about their survival or disease relapse. Additionally, sys-
temic chemotherapy after HR or RFA was not uniform
during the study period. Finally, the criteria used to select
treatment options at the time of diagnosis were not docu-
mented and were subject to individual physician decisions,
which might have caused inevitable selection bias. In the
future, a large-scale, well-controlled, prospective study is
needed to compare efficacy between RFA and HR for
patients with GC with liver metastases.
Despite these limitations, our results showed that the
RFA was not inferior to HR in terms of OS and can be
considered as a treatment option in selected patients. In
fact, for patients whose general condition often contrain-
dicates surgery, a less invasive ablative technique may
represent an interesting opportunity.
Conclusions
Hepatic resection may be the optimal treatment option
for gastric liver metastases. However, in patients who are
not candidates for surgical treatment (e.g., old age, co-
morbidities, poor general condition, bilobar distribution
of metastatic tumors, patient refusal), radiofrequency
ablation could be an alternative to hepatic resection. It is
Table 4 Treatment Outcome of individual patients
Clinical data Liver metastasis RFA Recur















1 No 0 1 Uni Meta 2.6 Yes 2 Yes Liver RFA 69.1 10.3 Death
2 Yes 1 1 Uni Meta 3.7 Yes 1 Yes Liver CTx 20.7 0.8 Death
3 No 0 5 Bi Meta 1 No 2 Yes Liver None 40.5 11.4 Death
4 No 1 2 Uni Syn 2 Yes 1 No 79.6 42.3 Alive
5 Yes 1 1 Uni Meta 1.7 No 1 Yes Liver RFA 21.8 4.7 Death
6 No 0 1 Uni Meta 3.3 Yes 1 No 22.9 22.6 Alive
7 Yes 1 1 Uni Meta 0.5 No 1 Yes
Virchow
Node
CTx 12.8 9.4 Alive
8 Yes 0 1 Uni Meta 1.5 No 1 Yes Lung None 25.1 8.9 Alive
9 Yes 2 1 Uni Meta 4.2 No 1 Yes Liver None 20.0 7.9 Alive
10 Yes 1 1 Uni Meta 3.7 No 1 No 3.6 3.3 Alive
11 No 2 2 Uni Meta 3.2 NO 1 No 15.3 14.4 Alive
PS, Performance status based on Eastern Cooperative Oncology Group, No number of metastatic lesion; Lobar, lobar distributaion; Uni, unilobar; Bi, bilobar; Meta,
metachronous; Syn synchronous, CTx chemotherapy, Recur recurrence, Tx treatment, OS overall survival, DFS disease free survival, mon months
aSurvival at the time of analysis
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a less invasive treatment option for liver metastases
alone from gastric cancer and offers these patients non-
inferior survival outcome to hepatic resection despite a
high recurrence rate.
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